drugset / Trial / NCT00146549
Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer
Phase 3
Completed
250 enrolled
Dana-Farber Cancer Institute
Brigham and Women's Hospital · collabGlaxoSmithKline · collabMassachusetts General Hospital · collabNorth Shore Medical Center · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare two different combinations of chemotherapy with trastuzumab as initial treatment for HER2 positive advanced breast cancer. Half of the patients will receive trastuzumab in combination with a taxane form of chemotherapy (either paclitaxel or docetaxel), while the other group will receive trastuzumab in combination with vinorelbine.
Timeline
- Start
- 2001-08
- Primary completion
- 2007-08
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Vinorelbine | Small molecule | — | — |
| Background | Trastuzumab | Monoclonal antibody | 2 mg/kg | — |